- Conditions
- Metabolic Syndrome, Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks, Screening, OGTT, Anthropometrics and Blood pressure, Blood Drawing
- Drug · Other
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Galveston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, Magnetic Resonance Imaging, Magrolimab, Resection
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 35 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 14
- States / cities
- Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- San Marcos, California
- Conditions
- Cystic Fibrosis
- Interventions
- Piperacillin-tazobactam combination product
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 8 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Tegavivint, Lenvatinib, Cabozantinib
- Drug
- Lead sponsor
- Iterion Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Duarte, California • Miami, Florida • Chicago, Illinois + 4 more
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
- Interventions
- pazopanib hydrochloride, iodine I 131
- Drug · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Parkinson's Disease
- Interventions
- XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa, Placebo for Sinemet
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 9 more
- Conditions
- HIV Infections, AIDS
- Interventions
- raltegravir, efavirenz
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Sacramento, California
- Conditions
- HEPATITIS C (HCV), Incarceration, Injection Drug Use, Implementation Science
- Interventions
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker
- Drug · Other
- Lead sponsor
- Lifespan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cranston, Rhode Island
- Conditions
- Opioid Use Disorder, Cigarette Smoking
- Interventions
- Telehealth Motivational Counseling, Nicotine Replacement Product, National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).
- Behavioral · Drug · Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • The Bronx, New York
- Conditions
- Metastatic Prostate Cancer
- Interventions
- AZD0516, AZD9574
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more
- Conditions
- Temporomandibular Joint Disorders
- Interventions
- Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel
- Behavioral · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hepatocellular Carcinoma, Hepatoma
- Interventions
- sorafenib, LC Bead-TACE
- Drug · Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- COVID-19, Long Haul
- Interventions
- Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach
- Drug · Diagnostic Test · Biological + 3 more
- Lead sponsor
- Well- Konnect Healthcare Services and Research Firm
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Cancer
- Interventions
- chemotherapy, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- sEphB4-HSA with chemotherapy, Cetuximab, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Type 2 Diabetes
- Interventions
- Digital Health Coaching, Continuous Glucose Monitoring Teleconsults
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cancer, Head and Neck Cancer, Pelvic Cancer, Nervous System Neoplasms, Thoracic Neoplasms
- Interventions
- Sunitinib, External Beam Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- PF-07248144, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 102
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more
- Conditions
- Alcohol Use Disorder (AUD)
- Interventions
- Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Renal Cell Carcinoma
- Interventions
- AGS-003, Sunitinib
- Biological · Drug
- Lead sponsor
- Argos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 12
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 9 more
- Conditions
- Menopause
- Interventions
- TSEC (Tissue-selective estrogen complexes), Placebo
- Drug · Other
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 50 Years to 60 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana